J. Goldman & Co’s Dyne Therapeutics DYN Stock Holding History

J. Goldman & Co’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-46,010	Closed	-$900K	–	722
2025 Q4	$900K	Buy	+46,010	New	+$871K	0.02%	397

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

J. Goldman & Co's DYN Position: Q1 2026 in Review

J. Goldman & Co sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 46,010 shares — an estimated $900K sold.

J. Goldman & Co first reported a position in DYN in Q4 2025 and held it in 1 quarter. The position peaked at $900K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

J. Goldman & Co reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 46,010 Dyne Therapeutics shares in Q1 2026, an estimated $900K.
J. Goldman & Co first reported a position in Dyne Therapeutics in Q4 2025 and held it in 1 quarter.
J. Goldman & Co's Dyne Therapeutics position peaked at $900K in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.